Free tool
FAERS Monitor: Diprivan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019627 or its brand name (Diprivan, Propofol). Reports on generic versions are filed under their own applications.
Reports
37,021
Serious
34,684
94% of reports
Hospitalization
15,860
Death reported
5,006
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension2,992
- drug ineffective2,858
- anaphylactic shock2,182
- cardiac arrest1,851
- anaphylactic reaction1,762
- off label use1,736
- drug interaction1,583
- tachycardia1,234
- bradycardia1,212
- acute kidney injury1,024
- pyrexia1,024
- rhabdomyolysis932
- bronchospasm833
- oxygen saturation decreased820
- renal failure820
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 583 |
| 2005 | 674 |
| 2006 | 630 |
| 2007 | 790 |
| 2008 | 798 |
| 2009 | 1,132 |
| 2010 | 976 |
| 2011 | 1,396 |
| 2012 | 1,186 |
| 2013 | 1,248 |
| 2014 | 1,148 |
| 2015 | 1,307 |
| 2016 | 1,622 |
| 2017 | 1,594 |
| 2018 | 2,060 |
| 2019 | 2,181 |
| 2020 | 2,738 |
| 2021 | 2,490 |
| 2022 | 2,361 |
| 2023 | 2,779 |
| 2024 | 2,477 |
| 2025 | 2,894 |
| 2026 | 1,944 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,017,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 2,182 | 52.4 | 50.3 | 100,884 |
| bronchospasmSignal | 833 | 35.2 | 32.8 | 26,013 |
| anaphylactic reactionSignal | 1,762 | 18.7 | 17.8 | 28,603 |
| bradycardiaSignal | 1,212 | 13.3 | 12.5 | 13,455 |
| cardiac arrestSignal | 1,851 | 13.0 | 12.4 | 20,122 |
| rhabdomyolysisSignal | 932 | 13.0 | 12.2 | 10,071 |
| hypotensionSignal | 2,992 | 8.6 | 8.3 | 19,941 |
| oxygen saturation decreasedSignal | 820 | 8.4 | 7.8 | 5,272 |
| tachycardiaSignal | 1,234 | 8.0 | 7.6 | 7,464 |
| drug interactionSignal | 1,583 | 5.7 | 5.4 | 6,140 |
| acute kidney injurySignal | 1,024 | 3.8 | 3.6 | 2,131 |
| renal failureSignal | 820 | 3.5 | 3.3 | 1,480 |
| pyrexia | 1,024 | 1.7 | 1.6 | 287 |
| drug ineffective | 2,858 | 1.2 | 1.2 | 133 |
| off label use | 1,736 | 1.1 | 1.1 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.